Evaluation of kisspeptin transport across the blood–brain barrier after intranasal administration
- Authors: Litvinova M.V.1, Lebedev A.A.1, Bychkov E.R.1, Shabanov P.D.1
-
Affiliations:
- Institute of Experimental Medicine
- Issue: Vol 23, No 2 (2025)
- Pages: 191-201
- Section: Original study articles
- URL: https://ogarev-online.ru/RCF/article/view/312497
- DOI: https://doi.org/10.17816/RCF676528
- EDN: https://elibrary.ru/JBKGXL
- ID: 312497
Cite item
Abstract
BACKGROUND: The kisspeptin family (KISS1), encoded by the kiss1 gene, is among the newly identified yet underexplored peptide families in terms of efficacy and intranasal delivery. Kisspeptins are involved not only in reproductive function but also in behavioral, emotional, and cognitive processes. Efficient delivery of kisspeptins to the central nervous system could open new perspectives for their application.
AIM: The work aimed to evaluate the efficacy of kisspeptin-10 transport across the blood–brain barrier after intranasal administration.
METHODS: The study included 45 outbred mice. Animals received kisspeptin-10 intranasally at doses of 0.1, 1, and 10 μg, and intraperitoneally at doses of 1, 10, and 100 μg. Animal behavior was assessed using the open field test, elevated plus maze, and sexual motivation test.
RESULTS: In the present study, stable and dose-dependent effects of kisspeptin-10 on mouse behavior were observed after intranasal administration. Intranasal kisspeptin-10 induced statistically significant increases in sexual motivation, horizontal and vertical locomotor activity, reduced anxiety, and enhanced exploratory behavior in sexually mature male mice. The most pronounced behavioral changes were produced by the 10 μg dose, exerting central effects after intranasal administration compared with the groups receiving intraperitoneal administration. In contrast, intraperitoneal kisspeptin-10 at doses of 1 μg and 10 μg produced virtually no behavioral changes. Increasing the intraperitoneal dose to 100 μg resulted in statistically significant behavioral changes; however, the effect was less pronounced than that observed after intranasal administration of 10 μg.
CONCLUSION: Statistically significant behavioral changes following intranasal administration required concentrations 10-fold lower than those needed for peripheral administration. Given the evident effects of intranasal kisspeptin-10 in each behavioral test, it can be assumed that kisspeptin-10 penetrated the brain, bypassing the blood–brain barrier, and exerted central effects. These findings support the potential feasibility and importance of this delivery route for targeting the central nervous system.
Full Text
##article.viewOnOriginalSite##About the authors
Maria V. Litvinova
Institute of Experimental Medicine
Author for correspondence.
Email: litvinova-masha@bk.ru
SPIN-code: 9548-4683
Russian Federation, Saint Petersburg
Andrei A. Lebedev
Institute of Experimental Medicine
Email: aalebedev-iem@rambler.ru
ORCID iD: 0000-0003-0297-0425
SPIN-code: 4998-5204
Dr. Sci. (Biology), Professor
Russian Federation, Saint PetersburgEugenii R. Bychkov
Institute of Experimental Medicine
Email: bychkov@mail.ru
ORCID iD: 0000-0002-8911-6805
SPIN-code: 9408-0799
MD, Dr. Sci. (Medicine)
Russian Federation, Saint PetersburgPetr D. Shabanov
Institute of Experimental Medicine
Email: pdshabanov@mail.ru
ORCID iD: 0000-0003-1464-1127
SPIN-code: 8974-7477
MD, Dr. Sci. (Medicine), Professor
Russian Federation, Saint PetersburgReferences
- Pfeferbaum B, North CS. Mental health and the COVID-19 pandemic. N Engl J Med. 2020;383(6):510–512. doi: 10.1056/NEJMp2008017
- Trofimov AN, Litvinova MV, Schwarz AP, et al. Molecular mechanisms of molecular transfer across the blood-brain barrier as a target for pharmacological action. Part 1. Structure, function and pathology of the BBB. Pharmacy Formulas. 2022;4(2):60–69. doi: 10.17816/phf109914 EDN: UQEDBL
- Profaci CP, Munji RN, Pulido RS, Daneman R. The blood–brain barrier in health and disease: important unanswered questions. J Exp Med. 2020;217(4):e20190062. doi: 10.1084/JEM.20190062/151582
- Litvinova MV, Tissen lY, Lebedev AA, et al. Influence of oxytocin on the central nervous system by different routes of administration. Psychopharmacology and biological narcology. 2023;14(2):139–148. doi: 10.17816/phbn501752 EDN: ANORKE
- Litvinova MV, Trofimov AN, Shabanov PD, et al. Molecular mechanisms of transport of substances across the blood-brain barrie as targets for pharmacological action. Part 2. Modern methods of delivery of pharmacological agents to the central nervous system. Pharmacy Formulas. 2022;4(3):82–96. doi: 10.17816/phf120109 EDN: QSCSBH
- Veronesi MC, Alhamami M, Miedema SB, et al. Imaging of intranasal drug delivery to the brain. Am J Nucl Med Mol Imaging. 2020;10(1):1–31.
- Tissen IYu, Chepik PA, Lebedev AA, et al. Conditioned place preference of kisspeptin-10. Reviews on Clinical Pharmacology and Drug Therapy. 2021;19(1):47–53. doi: 10.17816/RCF19147-53 EDN: SSEPQB
- Magarramova L, Tissen I, Blazhenko A, et al. Kisspeptin is testosterone independent regulator of sexual motivation in male rats. J Exp Biol Agric Sci. 2022;10(1):131–134. doi: 10.18006/2022.10(1).131.134
- Hellier V, Brock O, Candlish M, et al. Female sexual behavior in mice is controlled by kisspeptin neurons. Nat Commun. 2018;9(1):400. doi: 10.1038/s41467-017-02797-2
- Edouard GA, Mills KT, Comninos AN. Kisspeptin as a behavioral hormone. Semin Reprod Med. 2019;37(2):56–63. doi: 10.1055/s-0039-3400239
- Zhukov IS, Ptukha MA, Zolotoverkhaja EA, et al. Evaluation of approach to a conspecific and blood biochemical parameters in TAAR1 knockout mice. Brain Sci. 2022;12(5):614. doi: 10.3390/brainsci12050614
